The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
2021
-
Randomized Controlled Trial Multicenter Study
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear. ⋯ In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, assessed with the use of a 6-minute walk test, as compared with placebo. (Funded by United Therapeutics; INCREASE ClinicalTrials.gov number, NCT02630316.).